COVID-19 mRNA-1283 Vaccine Well-Tolerated, Noninferior To First-Generation mRNA-1273 Vaccine, Study Finds

Infectious Disease Advisor (8/13, Basilio) reports a study found that “the investigational COVID-19 mRNA-1283 vaccine is noninferior to the first-generation mRNA-1273 vaccine, eliciting higher neutralizing antibody (nAb) responses against Omicron and D614G mutations.” Study results “revealed 1177 COVID-19 events occurred during the study period, of which 560 (9.9%) were in the mRNA-1283 group and 617 (10.8%) were in the mRNA-1273 group.” The relative vaccine efficacy (VE) of mRNA-1283 was 9.3%, “indicating noninferiority between the vaccines.” The researchers also “noted the relative VE of mRNA-1283 differed across subgroups of patients aged 12 to 17 years (-29.2%), 18 to 64 years (9.7%), 50 years and older (15.0%), and 65 years and older (13.5%).” Furthermore, “the frequency of local adverse reactions frequencies was similar between patients who received mRNA-1283 vs mRNA-1273 (70.3% vs 78.4%).” The study was published in The Lancet Infectious Diseases.